Macimorelin

At Verified Peptides, we want to be transparent about classification upfront: Macimorelin is a non-peptide, peptidomimetic small molecule, not a genuine peptide. It is included in our Growth Hormone Secretagogue research category because it acts on the ghrelin/growth hormone secretagogue receptor (GHSR), the same receptor peptide-based secretagogues target, but its own chemistry is a small synthetic molecule rather than an amino acid chain — the same classification distinction that applies to Anamorelin, another non-peptide GHSR agonist in this catalog.

Macimorelin (free base CAS 381231-18-1, PubChem CID 9804938, molecular formula C26H30N6O3, molecular weight 474.55 g/mol) is marketed in its acetate salt form (CAS 945212-59-9, molecular formula C28H34N6O5, molecular weight 534.6 g/mol) under the brand name Macrilen, developed originally under codes AEZS-130, EP-1572, and JMV-1843. Unlike every other compound built so far in this Phase 3 batch, macimorelin holds a genuinely distinctive regulatory status: it is FDA-approved (since December 20, 2017) as an oral diagnostic agent for adult growth hormone deficiency (AGHD), and the European Medicines Agency granted marketing authorization in January 2019.

Macimorelin's approved clinical use is diagnostic, not therapeutic: a single oral dose is used to acutely stimulate growth hormone release as part of a stimulation test that helps clinicians determine whether a patient has adult growth hormone deficiency, rather than being administered repeatedly as an ongoing treatment the way most other compounds in this catalog are studied.

Adult growth hormone deficiency itself is a condition that can be difficult to diagnose with confidence, since GH secretion is naturally pulsatile and a single random blood draw is not diagnostically useful on its own -- this is precisely why stimulation tests, which measure the body's peak GH response to a standardized challenge, have long been the standard diagnostic approach, and why a validated, simpler stimulation test represented a genuine clinical need rather than a marginal improvement.

At Verified Peptides, we point researchers to the pivotal validation trial (Garcia JM, Biller BMK, et al., Journal of Clinical Endocrinology & Metabolism, 2018; PMID 29860473) as the primary published evidence supporting macimorelin's diagnostic use. This was a multicenter, open-label, randomized, two-way crossover trial (registered as ClinicalTrials.gov NCT02558829) comparing single-dose oral macimorelin against the insulin tolerance test in the same patients. Using a growth hormone cutoff of 2.8 ng/mL for macimorelin and 5.1 ng/mL for the ITT, the trial found 87% sensitivity and 96% specificity for macimorelin in diagnosing AGHD, with 95.38% negative agreement and 74.32% positive agreement between the two tests. In a post-hoc analysis using a matched 5.1 ng/mL cutoff for both tests, sensitivity rose to 92% with specificity remaining at 96%. Retest reproducibility for macimorelin was 97%, and no serious adverse events were reported.

This trial's conclusion — that oral macimorelin is a simple, well-tolerated, reproducible diagnostic test with accuracy comparable to the insulin tolerance test — was the basis for FDA approval in December 2017 and subsequent EMA marketing authorization in January 2019. This clinical validation and approval history is notably more complete than most other compounds in this Phase 3 batch, reflecting macimorelin's status as an approved diagnostic drug rather than an investigational compound.

More recent published research (PMID 36694890, 2023) has extended macimorelin's validation to childhood-onset growth hormone deficiency diagnosis, an application distinct from its original adult-onset AGHD approval, suggesting continued research interest in expanding its validated diagnostic uses beyond the original approved indication.

The pediatric validation work is methodologically notable in its own right, since children and adolescents present distinct challenges for GH stimulation testing compared with adults -- growth patterns, pubertal status, and different established diagnostic cutoffs all need separate validation rather than simply extrapolating adult cutoff values downward, which is part of why this research is treated as a genuinely separate validation effort rather than a simple confirmation of the adult findings.

Despite this approved-drug status for its pharmaceutical formulation (Macrilen), research-grade macimorelin sold here is a separate, non-clinical product intended exclusively for laboratory research, not for human or animal diagnostic or therapeutic use.

Macimorelin is one of only two compounds in this Phase 3 build with a real regulatory approval already in place, but its approval is diagnostic rather than therapeutic — a distinction worth understanding clearly. The FDA approved macimorelin specifically as a test to help diagnose a condition (adult growth hormone deficiency), not as a treatment for any condition. This is a meaningfully different regulatory category from a therapeutic drug, even though the underlying chemistry (a GHSR agonist) is the same class of compound studied for therapeutic purposes elsewhere.

The insulin tolerance test that macimorelin was validated against remains, in many clinical contexts, considered the historical reference-standard diagnostic for AGHD, but it carries real clinical risk (deliberately inducing hypoglycemia) and requires intensive monitoring, making it unsuitable for some patients. Macimorelin's development was driven substantially by the clinical need for a safer, simpler alternative — a notable example of a diagnostic tool being developed to replace a risk-carrying reference standard rather than to treat a previously untreatable condition.

Macimorelin and Anamorelin are both non-peptide, peptidomimetic ghrelin receptor agonists, developed independently for entirely different purposes — Macimorelin as a single-dose diagnostic agent, Anamorelin for chronic-use appetite and lean-body-mass support in cancer cachexia. Researchers should not assume similar dosing, safety, or use patterns between the two based solely on their shared receptor mechanism, since their entire clinical development programs were designed around different administration patterns and endpoints.

The VA (U.S. Department of Veterans Affairs) played a documented role in supporting the research validating macimorelin's diagnostic use, reflecting institutional research interest in improving AGHD diagnostic pathways for veteran populations specifically, alongside the broader multicenter trial program.

Prior to macimorelin's approval, other GH stimulation tests beyond the insulin tolerance test were also in clinical use, including the arginine stimulation test and the glucagon stimulation test, each with its own combination of accuracy, practicality, and risk tradeoffs. Macimorelin's validation program specifically targeted the insulin tolerance test as its comparator because the ITT was considered the most diagnostically robust of the existing options, meaning macimorelin needed to demonstrate accuracy against the toughest available benchmark rather than an easier one, which strengthens the clinical credibility of its validated performance.

At Verified Peptides, we require independent third-party HPLC purity testing and mass spectrometry or equivalent analytical identity confirmation for every batch of research-grade macimorelin we offer, with a Certificate of Analysis (COA) available for each lot. As a small molecule rather than a peptide, macimorelin's synthesis and quality-control process differs from solid-phase peptide synthesis, and verification should reflect small-molecule pharmaceutical chemistry standards.

We source exclusively from manufacturers operating under Good Manufacturing Practice (GMP)-aligned quality systems, and every lot is independently verified rather than accepted solely on a supplier's internal documentation. Researchers should request and review the specific COA for their lot, confirming purity percentage and molecular identity, before use in any experimental protocol.

Given that macimorelin's validated clinical use depends on precise, reproducible GH stimulation for diagnostic accuracy, purity and identity verification are especially relevant considerations for any research modeling its diagnostic mechanism, since an impure or misidentified sample could meaningfully confound a reproducibility-focused research question.

Macimorelin, as a small-molecule compound rather than a lyophilized peptide, should be stored according to the specific stability guidance provided on the Certificate of Analysis for each lot, generally at room temperature or refrigerated, protected from light and moisture.

Small-molecule compounds like macimorelin are generally more chemically stable in solid form than reconstituted peptide solutions, and storage requirements tend to be less stringent than for lyophilized peptides requiring cold-chain handling after reconstitution. Researchers should nonetheless follow the specific lot documentation provided with each order rather than assuming stability based on general small-molecule chemistry principles alone.

As with any research compound, prolonged exposure to heat, direct light, or humidity can accelerate degradation and compromise the material's relevance to research applications. Following the lot-specific storage guidance provided with each order remains the most reliable way to preserve sample validity for experimental work.